SAN FRANCISCO — Ophthalmic innovations are steadily moving forward, but not quite at the rate of other specialties, Emmett T. Cunningham, Jr., MD, PhD, MPH, explained during the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology annual meeting.
Cunningham’s 2019 Year in Review discussion detailed a robust year for FDA new molecular entity approvals; however, ophthalmology has garnered only one approved biologics license application and six new drug application approvals this year.
“Ophthalmology has normally one or two new molecular entities, but
Uncategorized